Fig 1.
Process of screening edaravone for adverse events associated with different routes of administration from the US Food and Drug Administration adverse event reporting database.
Table 1.
clinical characteristics of patients with adverse events under different administration routes of Edaravone.
Table 2.
the two-by-two contingency table.
Table 3.
AE signal intensity for oral administration.
Table 4.
AE signal intensity for intravenous administration.
Fig 2.
Analysis of differential risk signals for different administration routes of Edaravone.
(A)CI, confidence interval;(B)ROR, reporting odds ratio; (C)a, number of cases with suspected AEs associated with the target drug.
Fig 3.
The induction time of adverse reactions associated with different routes of administration.
Table 5.
The analysis of the onset time of priority signals for intravenous injection and oral administration.